SLC1A1

Excitatory amino acid transporter 3 · P43005 · SLC1A1 on Sugi Atlas →

81,106 patent compounds predicted against SLC1A1, 46,330 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Leucine (SCHEMBL67322)	0.60	7/20
Leucine (SCHEMBL122270)	0.52	7/20
Leucine (SCHEMBL122271)	0.52	7/20
Leucine (SCHEMBL138874)	0.47	7/20
SCHEMBL30895	1.00	6/20
SCHEMBL71719	1.00	6/20
Leucine (SCHEMBL165422)	0.48	6/20
SCHEMBL157396	0.41	6/20
SCHEMBL136824	0.70	5/20
Norvaline (SCHEMBL167258)	0.59	5/20
Norvaline (SCHEMBL167259)	0.59	5/20
SCHEMBL39093	0.56	5/20
SCHEMBL148584	0.56	5/20
SCHEMBL125406	0.54	5/20
Aspartic Acid (SCHEMBL135731)	0.52	5/20
Valine (SCHEMBL111113)	0.38	5/20
Glutamic Acid (SCHEMBL24357)	0.72	4/20
Norleucine (SCHEMBL26474)	0.67	4/20
Valproic Acid (SCHEMBL2275)	0.62	4/20
Valproic Acid (SCHEMBL140241)	0.62	4/20

Clinical trials — most relevant to SLC1A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine	PHASE4	COMPLETED
Effects of Kuvan on Melatonin Secretion	PHASE4	COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	PHASE1/PHASE2	RECRUITING
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis	PHASE2	UNKNOWN
Ketamine Infusion for Obsessive-Compulsive Disorder	PHASE2	COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
DAAOI-1 Treatment for Treatment-resistant Schizophrenia	PHASE2	COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia	PHASE2	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
Study on Amino Acid Uptake in Brain Tumors	PHASE2	UNKNOWN
Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD)	PHASE2	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study	PHASE1	UNKNOWN
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
Stem Cell Study of Genetics and Drug Addiction	nan	COMPLETED
A Study of Cases with Abnormal Serum Ammonia in Neonate and Children Attending Assiut University Children Hospital	nan	NOT_YET_RECRUITING
sCD163 in ALS Patients	nan	COMPLETED
Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue	nan	NOT_YET_RECRUITING
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy	nan	UNKNOWN
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder	nan	UNKNOWN
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle	nan	COMPLETED
Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers	nan	COMPLETED
Effects of Sulfasalazine on BOLD Response to Alcohol Cues	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC1A1 binder may also engage these)

Protein	Name	Similarity
P31597	—	1.000	P31597 →
P51907	—	1.000	P51907 →
P51906	—	0.998	P51906 →
Q95135	—	0.998	Q95135 →
SLC1A3	Excitatory amino acid transporter 1	0.993	landscape →
P31596	—	0.992	P31596 →
O57321	—	0.992	O57321 →
SLC1A2	Excitatory amino acid transporter 2	0.991	landscape →
P43006	—	0.991	P43006 →
P46411	—	0.991	P46411 →
P24942	—	0.991	P24942 →
P56564	—	0.990	P56564 →
Q25605	—	0.990	Q25605 →
Q10901	—	0.989	Q10901 →
O00341	—	0.989	O00341 →
Q8JZR4	—	0.988	Q8JZR4 →
O35544	—	0.981	O35544 →
O35921	—	0.980	O35921 →
Q21353	—	0.979	Q21353 →
Q9N1R2	—	0.976	Q9N1R2 →
P48664	—	0.975	P48664 →
Q22682	—	0.971	Q22682 →
Q8C0X2	—	0.968	Q8C0X2 →
Q7T2C4	—	0.968	Q7T2C4 →
P51912	—	0.968	P51912 →
Q9JKQ2	—	0.966	Q9JKQ2 →
Q21751	—	0.965	Q21751 →
P35449	—	0.963	P35449 →
P58743	—	0.963	P58743 →
O35874	—	0.962	O35874 →